Research Use Only — Confirm to Continue

OptimalDosages.com publishes reference material for laboratory and educational use. Nothing here is medical advice, a prescription, or a recommendation for human administration.

By continuing you confirm you are 21 or older and that you are accessing this material in a research or educational capacity.

Research Use Only · Dosing data compiled from published literature · Not for human or veterinary use

CJC-1295 DAC Dosage & Reconstitution

CJC-1295 with drug affinity complex. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: clinical.

1Set Up Your Mix

4 mg/mL · 4000 mcg/mL
All answers assume a standard 1 mL U-100 syringe, where 1 unit = 0.01 mL. That is the usual insulin syringe and the one every number here is based on.

Your Answer — CJC-1295 DACYour Answer

50Draw To This Line
0.5That's This Many mL
1Doses In The Vial
0102030405060708090100 U-100 syringe · 1 mL · 100 units draw to 50
2 mg ÷ 0.5 mL = 4 mg/mL  →  2 mg ÷ 4 mg/mL = 0.5 mL  →  × 100 = 50 units
Looks good. Draw to 50 units on a 1 mL syringe. That is an easy amount to measure, and this vial gives you 1 doses.

2Week-By-Week Plan — CJC-1295 DAC

Start low, work up
WhenDoseHow OftenHow Many mLDraw ToNumber Of DosesPeptide Used
Low reported 1 mg once weekly 0.25 mL 25 u 2 doses
Standard 2 mg once weekly 0.5 mL 50 u 1 doses
Trial dose30–60 mcg/kg weekly Set by body weight — can't be turned into a single amount to draw
Weeks until the top dose
4 weeks
Peptide used getting there
4 mg
Vials you'll need
2 × 2 mg
Once you're at the top dose
8 mg / 4 wk · 4 vials
Where this plan came from
Built from this peptide's dose range
Where this came from: Built from the doses listed for this peptide below — start at the lowest and step up, using the studies cited on this page. Nobody publishes a week-by-week plan for this peptide, so we built one: the doses are the researched ones shown below, and we simply put them in order from lowest to highest. Treat it as a starting point, not an official schedule.

3Common Doses — CJC-1295 DAC

worked out for your mix
LevelDoseHow OftenHow Many mLDraw ToDoses In Vial
Weeks 1–4 1 mg once weekly 0.25 mL 25 u 4 4 mg
Week 5 onward
per 4 weeks from here on
2 mg once weekly 0.5 mL 50 u 4 8 mg
Please read this. These numbers come from published research. They are here as reference, not as instructions. A lot of them come from lab studies rather than studies in people, and some of these peptides have never been given to a person at all.

About CJC-1295 DACAbout This Peptide

GH Secretagogue
Also known as
CJC-1295 with drug affinity complex
Class
GH Secretagogue
Route
Subcutaneous
Half-life
~6–8 days
Evidence tier
Clinical

GHRH analogue conjugated to bind serum albumin, extending half-life from minutes to days. This produces sustained GH/IGF-1 elevation rather than pulses — a meaningfully different physiological profile from the no-DAC version.

Buy CJC-1295 DACthis peptide

Opens optimal-pep.com in a new tab

Where These Numbers Come From

Clinical — Human trial or approved-label dosing published
Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analogue of GHRH Teichman SL, et al. JCEM, 2006
The human dose-escalation study; source of the mcg/kg figures.
Find on PubMed ↗

Newest Studies —

Not reviewed by us. This list is pulled straight from Europe PMC as papers are published. Nobody has checked whether these are any good, or whether they change anything above. The dose numbers on this page only ever change after a person reviews the evidence.

More peptides

Browse the full catalogue, or jump to a neighbouring compound.

CJC-1295 (no DAC)

A tetra-substituted GHRH(1-29) analogue without the drug affinity complex, giving a short pulse rather than sustained elevation. F…

Sermorelin

The natural GHRH 1-29 fragment. Previously an approved agent for paediatric GH deficiency diagnosis and treatment before withdrawa…

All 71 peptides

Every compound compared in one table: dose range, how often, half-life and evidence tier.